Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6% - What's Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) traded down 6% during trading on Wednesday . The company traded as low as $17.61 and last traded at $17.06. 3,638 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 274,140 shares. The stock had previously closed at $18.14.

Analyst Ratings Changes

Several research firms have recently weighed in on DNTH. Robert W. Baird decreased their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $53.00.

Dianthus Therapeutics Trading Down 2.6%

The firm has a market capitalization of $567.95 million, a price-to-earnings ratio of -6.13 and a beta of 1.36. The company has a 50-day moving average of $19.20 and a 200-day moving average of $20.76.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. The business had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. On average, research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC lifted its position in Dianthus Therapeutics by 160.2% in the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company's stock worth $1,972,000 after buying an additional 55,682 shares in the last quarter. Northern Trust Corp increased its stake in shares of Dianthus Therapeutics by 21.2% in the fourth quarter. Northern Trust Corp now owns 245,523 shares of the company's stock worth $5,352,000 after acquiring an additional 42,923 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Dianthus Therapeutics by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after acquiring an additional 136,633 shares in the last quarter. Vestal Point Capital LP boosted its position in Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after purchasing an additional 680,000 shares during the last quarter. Finally, FMR LLC boosted its position in Dianthus Therapeutics by 0.8% during the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after purchasing an additional 36,133 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.